


Protein Quantification Bridging ELISA Series


for Development of Drug Antibodies



- 專為抗體藥物開發設計的 Bridging ELISA Kit。
- 屬 Sandwich ELISA，設計成可專一性結合抗體藥之抗原辨識區，以確保偵測到的抗體藥分子皆具有抗原結合活性。
- 可同時定量與確認治療性抗體的結構，減少檢驗時間與樣品消耗。
- 適合 Drug Antibodies (DA) 的開發，可進行抗體藥藥物動力學及免疫原性檢測，亦可應用於製程評估。

Monoclonal Drug Antibodies & Biosimilars

Bridging ELISA可應用於檢測抗體藥之藥物動力學(Pharmacokinetic, PK)，即抗體藥在動物體內之濃度變化及代謝情形。藥物須停留於體內足夠時間以發揮功效，亦須能被生物體代謝清除。抗體藥上市前會經過嚴格測試，因此，當研發新的抗體藥搭配其他藥物時(抗體藥或小分子)，亦須重新檢測抗體藥的PK。此外，當廠商欲發展生物性相似藥 (Biosimilars)，同時須提出能力測試證明與市面上抗體藥具有相同的藥物特性。




Product Code	Detect target	General trade name	Product Name
EAD-Adal	Adalimumab (Target: TNF α)	Humira	Adalimumab ELISA
EAD-Atez	Atezolizumab (Target: PD-L1)	Tecentriq	Atezolizumab ELISA
EAD-Beva	Bevacizumab (Target: VEGF-A)	Avastin	Bevacizumab ELISA
EAD-Cetu	Cetuximab (Target: EGF receptor)	Erbix	Cetuximab ELISA
EAD-Dara	Daratumumab (Target: CD38)	Darzalex	Daratumumab ELISA
EAD-Deno	Denosumab (Target: RANKL)	Prolia/Xgeva	Denosumab ELISA
EAD-Dupi	Dupilumab (Target: IL-4R α)	Dupilixent	Dupilumab ELISA
EAD-Ecul	Eculizumab (Target: Complement C5)	Soliris	Eculizumab ELISA
EAD-Goli	Golimumab (Target: TNF α)	Simponi	Golimumab ELISA
EAD-Infl	Infliximab (Target: TNF- α)	Remicade	Infliximab ELISA
EAD-Nivo	Nivolumab (Target: PD-1)	Opdivo	Nivolumab ELISA
EAD-Ocre	Ocrelizumab (Target: CD20)	Ocrevus	Ocrelizumab ELISA
EAD-Omal	Omalizumab (Target: human IgE)	Xolair	Omalizumab ELISA
EAD-Pert	Pertuzumab (Target: HER2)	Perjeta	Pertuzumab ELISA
EAD-Pemb	Pembrolizumab (Target: PD-1)	Keytruda	Pembrolizumab ELISA
EAD-Ranib	Ranibizumab (Target: VEGF-A)	Lucentis	Ranibizumab ELISA
EAD-Ritu	Rituximab (Target: CD20)	Rituxan	Rituximab ELISA
EAD-Secu	Secukinumab (Target: IL17A)	Cosentyx	Secukinumab ELISA
EAD-Toci	Tocilizumab (Target: IL-6 receptor)	Actemra	Tocilizumab ELISA
EAD-Tras	Trastuzumab (Target: HER2)	Herceptin	Trastuzumab ELISA
EAD-Uste	Ustekinumab (Target: IL-12 & IL-23)	Stelara	Ustekinumab ELISA
EAD-Vedo	Vedolizumab (Target: Integrin $\alpha4\beta7$)	Entyvio	Vedolizumab ELISA

Bridging ELISA

讓您不再為標準品煩惱

Anti-Drug Antibodies (ADA)

Bridging ELISA亦可作為研究 Anti-Drug Antibody (ADA, 抗藥物抗體) 的陽性對照組。進入生物體內的抗體藥屬於外源分子, 即便抗體藥已經過優化, 仍有可能引起免疫反應。會刺激免疫系統產生非預期性抗體, 即為 ADA。ADA的產生表示抗體藥將更容易被生物體代謝清除, 導致抗體藥療效降低, 更有可能引發自體免疫反應等副作用的產生。因此監測生物體內的 ADA對於開發及評估抗體藥是很重要的依據。



Code	Detect target	General trade name	Product Name
EAD-AnAdal	Anti-Adalimumab	Humira	Anti-Adalimumab ELISA
EAD-AnAtez	Anti-Atezolizumab	Tecentriq	Anti-Atezolizumab ELISA
EAD-AnBeva	Anti-Bevacizumab	Avastin	Anti-Bevacizumab ELISA
EAD-AnCetu	Anti-Cetuximab	Erbix	Anti-Cetuximab ELISA
EAD-AnDara	Anti-Daratumumab	Darzalex	Anti-Daratumumab ELISA
EAD-AnDeno	Anti-Denosumab	Prolia/Xgeva	Anti-Denosumab ELISA
EAD-AnDupi	Anti-Dupilumab	Dupixent	Anti-Dupilumab ELISA
EAD-AnEcul	Anti-Eculizumab	Soliris	Anti-Eculizumab ELISA
EAD-AnGoli	Anti-Golimimumab	Simponi	Anti-Golimimumab ELISA
EAD-AnInfl	Anti-Infliximab	Remicade	Anti-Infliximab ELISA
EAD-AnNivo	Anti-Nivolumab	Opdivo	Anti-Nivolumab ELISA
EAD-AnOcre	Anti-Ocrelizumab	Ocrevus	Anti-Ocrelizumab ELISA
EAD-AnOmal	Anti-Omalizumab	Xolair	Anti-Omalizumab ELISA
EAD-AnPert	Anti-Pertuzumab	Perjeta	Anti-Pertuzumab ELISA
EAD-AnPemb	Anti-Pembrolizumab	Keytruda	Anti-Pembrolizumab ELISA
EAD-AnRanib	Anti-Ranibizumab	Lucentis	Anti-Ranibizumab ELISA
EAD-AnRitu	Anti-Rituximab	Rituxan	Anti-Rituximab ELISA
EAD-AnSecu	Anti-Secukinumab	Cosentyx	Anti-Secukinumab ELISA
EAD-AnToci	Anti-Tocilizumab	Actemra	Anti-Tocilizumab ELISA
EAD-AnTras	Anti-Trastuzumab	Herceptin	Anti-Trastuzumab ELISA
EAD-AnUste	Anti-Ustekinumab	Stelara	Anti-Ustekinumab ELISA
EAD-AnVedo	Anti-Vedolizumab	Entyvio	Anti-Vedolizumab ELISA

THLS-2208-03-022



LINE@



客戶滿意度



FB



IG